Citigroup Inc Gamida Cell Ltd. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$1.53 - $3.39 $24 - $54	-16 Reduced 1.76%	893 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.73 - $4.29 $640 - $1,587	-370 Reduced 28.93%	909 $2,000
Q1 2022 May 12, 2022	SELL	$2.22 - $4.47 $1,163 - $2,342	-524 Reduced 29.06%	1,279 $5,000
Q4 2021 Feb 10, 2022	SELL	$2.2 - $4.46 $2,857 - $5,793	-1,299 Reduced 41.88%	1,803 $5,000
Q3 2021 Nov 10, 2021	BUY	$3.85 - $6.44 $11,942 - $19,976	3,102 New	3,102 $12,000

11.4M

235K

70.5K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.